Loading
JUN (Transcription factor Jun) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Skin cancer and Melanoma.
Transcription factor that recognises and binds to the AP-1 consensus motif 5'-TGA[GC]TCA-3'. Heterodimerises with proteins of the FOS family to form an AP-1 transcription complex, thereby enhancing its DNA binding activity to the AP-1 consensus sequence 5'-TGA[GC]TCA-3' and enhancing its transcriptional activity. Together with FOSB, plays a role in activation-induced cell death of T cells by binding to the AP-1 promoter site of FASLG/CD95L, and inducing its transcription in response to activation of the TCR/CD3 signalling pathway.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Irbesartan. Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes literature 1.00, affected pathway 0.71, animal model 0.33, somatic mutation 0.96).
In plain words · JUN (Transcription factor Jun) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Skin cancer and Melanoma.
JUN (Transcription factor Jun) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Skin cancer and Melanoma.
Transcription factor that recognises and binds to the AP-1 consensus motif 5'-TGA[GC]TCA-3'.
No product in this corpus aims at JUN yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA JUN: RNA low tissue specificity; high antibody staining in 8 normal tissues; highest cancer staining cervical cancer (10 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Colorectal cancer, Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas JUN tissue; Open Targets ENSG00000177606 associations
First described 1987. Earliest sequence paper UniProt cites for the protein: Bohmann et al, Science, 1987, "Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1". Source.
Sources: HGNC HGNC:6204 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P05412 (protein name, function text, keywords and locations (REST API)); CIViC gene JUN (1 evidence items, 0 assertions, 1 variants; diseases: Colorectal Adenocarcinoma (GraphQL API, CC0)); Open Targets ENSG00000177606 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: colorectal cancer 0.54, melanoma 0.56, skin cancer 0.56 (GraphQL API, CC0))
Transcription factor that recognises and binds to the AP-1 consensus motif 5'-TGA[GC]TCA-3'. Heterodimerises with proteins of the FOS family to form an AP-1 transcription complex, thereby enhancing its DNA binding activity to the AP-1 consensus sequence 5'-TGA[GC]TCA-3' and enhancing its transcriptional activity. Together with FOSB, plays a role in activation-induced cell death of T cells by binding to the AP-1 promoter site of FASLG/CD95L, and inducing its transcription in response to activation of the TCR/CD3 signalling pathway. Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signalling pathway stimulation. Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells. Binds to the USP28 promoter in colorectal cancer (CRC) cells. Location: Nucleus (UniProt). Locus 1p32.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Appendix, Breast, Cervix, Colon, Duodenum, Fallopian tube, Lung, Nasopharynx.
Medium only: carcinoid, lymphoma, stomach cancer, thyroid cancer.
HPA JUN tissue · HPA JUN pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"JUN" OR ABSTRACT:"JUN" OR TITLE:"Jun proto-oncogene, AP-1 transcription factor subunit" OR ABSTRACT:"Jun proto-oncogene, AP-1 transcription factor subunit" OR TITLE:"Transcription factor Jun" OR ABSTRACT:"Transcription factor Jun" OR TITLE:"c-Jun" OR ABSTRACT:"c-Jun" OR TITLE:"AP-1" OR ABSTRACT:"AP-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JUN, not a curated reading list.